Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OS 2966

Next Previous
Search
Drug Profile

OS 2966

Alternative Names: OS-2966; OS2966t

Latest Information Update: 22 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoSynergy
  • Class Antineoplastics; Antipsoriatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD29 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioblastoma
  • Preclinical Acute myeloid leukaemia; Breast cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Psoriasis; Traumatic brain injuries
  • No development reported Solid tumours
  • Discontinued Ebola virus infections

Most Recent Events

  • 22 Oct 2024 Preclinical trials in Breast cancer in USA (unspecified route) (OncoSynergy pipeline, October 2024)
  • 22 Oct 2024 Preclinical trials in Ovarian cancer in USA (unspecified route) (OncoSynergy pipeline, October 2024)
  • 18 Mar 2024 OS 2966 is still in phase-I development in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top